AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the ... - PR Newswire
| OSE Stock | EUR 7.80 0.41 4.99% |
About 62% of OSE Pharma's investor base is looking to short. The analysis of current outlook of investing in OSE Pharma SA suggests that many traders are alarmed regarding OSE Pharma's prospects. The current market sentiment, together with OSE Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use OSE Pharma SA stock news signals to limit their universe of possible portfolio assets.
OSE |
AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the ... PR Newswire
Read at news.google.com
 |
OSE Pharma Fundamental Analysis
We analyze OSE Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OSE Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OSE Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
OSE Pharma is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
OSE Pharma SA Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with OSE Pharma stock to make a market-neutral strategy. Peer analysis of OSE Pharma could also be used in its relative valuation, which is a method of valuing OSE Pharma by comparing valuation metrics with similar companies.
Peers
OSE Pharma Related Equities
| IPH | Innate Pharma | 22.58 | ||||
| VLA | Valneva SE | 0.54 | ||||
| NANO | Nanobiotix | 2.13 | ||||
| POXEL | Poxel SA | 7.69 |
Complementary Tools for OSE Stock analysis
When running OSE Pharma's price analysis, check to measure OSE Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OSE Pharma is operating at the current time. Most of OSE Pharma's value examination focuses on studying past and present price action to predict the probability of OSE Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OSE Pharma's price. Additionally, you may evaluate how the addition of OSE Pharma to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |